These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3187292)

  • 21. Reduced-intensity unrelated cord blood transplantation for treatment of metastatic renal cell carcinoma: first evidence of cord-blood-versus-solid-tumor effect.
    Takami A; Takamatsu H; Yamazaki H; Ishiyama K; Okumura H; Ohata K; Konaka H; Asakura H; Namiki M; Nakao S
    Bone Marrow Transplant; 2006 Dec; 38(11):729-32. PubMed ID: 17028623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pain management, supportive and palliative care in patients with renal cell carcinoma.
    Turner JS; Cheung EM; George J; Quinn DI
    BJU Int; 2007 May; 99(5 Pt B):1305-12. PubMed ID: 17441929
    [No Abstract]   [Full Text] [Related]  

  • 23. Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group.
    Bukowski RM; Negrier S; Elson P
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6310S-4S. PubMed ID: 15448023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Editorial comment on: Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
    Novara G
    Eur Urol; 2009 May; 55(5):1153-4. PubMed ID: 18930580
    [No Abstract]   [Full Text] [Related]  

  • 25. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
    Belldegrun A; Shvarts O; Figlin RA
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Preliminary findings on clinical and immunological effects of subcutaneously administered interleukin-2 + alpha-interferon combination in the treatment of advanced renal carcinoma].
    Buda F; Buda C; Croatto T; Costa B; Aragona P; Tuveri G
    Recenti Prog Med; 1995; 86(7-8):304-5. PubMed ID: 7569288
    [No Abstract]   [Full Text] [Related]  

  • 27. Natural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation.
    Nakayama K; Tannir NM; Liu P; Wathen JK; Cheng YC; Champlin RE; Ueno NT
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):975-85. PubMed ID: 17640602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conclusion and future directions.
    Samlowski WE; Vogelzang NJ
    Cancer J; 2008; 14(5):330-2. PubMed ID: 18836339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma.
    Stadler WM; Vogelzang NJ
    Semin Oncol; 1995 Feb; 22(1):67-73. PubMed ID: 7855621
    [No Abstract]   [Full Text] [Related]  

  • 30. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome.
    Wood CG
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):697s-702s. PubMed ID: 17255296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Long-term results of endovascular treatment of metastatic renal cell cancer].
    Granov AM; Gorelov AI; Shumskiĭ IA; Polikarpov AA; Shkol'nik MI; Vorob'ev MI; Karelin MI
    Vestn Rentgenol Radiol; 1999; (6):20-3. PubMed ID: 10714226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal cell carcinoma with inferior vena cava invasion: an orphan disease?
    Patard JJ
    Eur Urol; 2006 Aug; 50(2):208-10. PubMed ID: 16626854
    [No Abstract]   [Full Text] [Related]  

  • 33. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transfusion-related acute lung injury (TRALI) following platelet transfusion in a patient receiving high-dose interleukin-2 for treatment of metastatic renal cell carcinoma.
    Medeiros BC; Kogel KE; Kane MA
    Transfus Apher Sci; 2003 Aug; 29(1):25-7. PubMed ID: 12877889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Outcome of patients in metastatic renal cell carcinoma with or without embolization].
    Masuda F; Nakada J; Takasaka S; Hishinuma H
    Hinyokika Kiyo; 1987 Sep; 33(9):1354-6. PubMed ID: 3434491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multimodality treatment of metastatic renal cell carcinoma.
    Mickisch GH
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):681-5. PubMed ID: 12503214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy.
    Lam JS; Belldegrun AS; Figlin RA
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6304S-9S. PubMed ID: 15448022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The problematic nature of metastasized renal cell carcinoma.
    Bichler KH; Wechsel HW
    Anticancer Res; 1999; 19(2C):1463-6. PubMed ID: 10365124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy of renal cell carcinoma with granulocyte macrophage colony stimulating factor and very low dose interleukin-2.
    Correale P; Marsili S; Sabatino M; Montagnani F; Giorgi G; Francini G
    Oncol Rep; 2005 Apr; 13(4):751-6. PubMed ID: 15756453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.